Amgen, Inc. (AMGN) Shares Sold by Check Capital Management Inc. CA
Check Capital Management Inc. CA decreased its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 17.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,080 shares of the medical research company’s stock after selling 650 shares during the quarter. Check Capital Management Inc. CA’s holdings in Amgen were worth $530,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Financial Advisory Service Inc. increased its stake in shares of Amgen by 0.3% in the second quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock valued at $340,000 after buying an additional 5 shares during the period. Jackson Grant Investment Advisers Inc. increased its stake in shares of Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after buying an additional 5 shares during the period. Capital Advisors Ltd. LLC increased its stake in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock valued at $190,000 after buying an additional 7 shares during the period. Ballentine Partners LLC increased its stake in shares of Amgen by 0.3% in the second quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock valued at $620,000 after buying an additional 9 shares during the period. Finally, Hudock Capital Group LLC increased its stake in shares of Amgen by 0.5% in the second quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock valued at $330,000 after buying an additional 10 shares during the period. 78.38% of the stock is owned by hedge funds and other institutional investors.
Amgen, Inc. (NASDAQ AMGN) opened at $176.22 on Thursday. The stock has a market capitalization of $129,712.96, a P/E ratio of 14.20, a price-to-earnings-growth ratio of 2.59 and a beta of 1.36. Amgen, Inc. has a twelve month low of $138.83 and a twelve month high of $191.10. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05.
Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The company had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. During the same period in the prior year, the firm earned $3.02 earnings per share. Amgen’s revenue for the quarter was down .7% on a year-over-year basis. sell-side analysts anticipate that Amgen, Inc. will post 12.66 earnings per share for the current fiscal year.
Amgen declared that its Board of Directors has authorized a share repurchase program on Wednesday, October 25th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be given a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.61%. The ex-dividend date is Thursday, November 16th. Amgen’s payout ratio is 41.63%.
In other news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $171.58, for a total transaction of $261,659.50. Following the transaction, the executive vice president now directly owns 57,631 shares of the company’s stock, valued at $9,888,326.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. Insiders have sold 7,050 shares of company stock worth $1,239,673 over the last ninety days. 0.19% of the stock is owned by insiders.
Several research analysts have recently issued reports on the company. Zacks Investment Research downgraded Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Royal Bank Of Canada lowered their price objective on Amgen from $192.00 to $188.00 and set a “sector perform” rating for the company in a research note on Thursday, October 26th. Credit Suisse Group reaffirmed a “neutral” rating and issued a $186.00 price objective (up previously from $177.00) on shares of Amgen in a research note on Friday, September 29th. Oppenheimer reaffirmed a “buy” rating and issued a $203.00 price objective on shares of Amgen in a research note on Thursday, September 7th. Finally, BMO Capital Markets reaffirmed a “hold” rating and issued a $199.00 price objective on shares of Amgen in a research note on Monday, September 25th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. Amgen has a consensus rating of “Hold” and an average target price of $190.22.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.